Clinical Trials Logo

Dysphoria clinical trials

View clinical trials related to Dysphoria.

Filter by:
  • None
  • Page 1

NCT ID: NCT05061745 Recruiting - Dysphoria Clinical Trials

Neuromodulation for Dysphoria

Start date: September 29, 2021
Phase: N/A
Study type: Interventional

This is an open label prospective pilot study of two neuromodulation interventions for patients suffering from dysphoria. Dysphoria is a transdiagnostic symptom of unease or dissatisfaction experienced across a range of diagnoses, including mood disorders and pain. There is a significant gap of treatment options across conditions with dysphoria, particularly non-medicated and self-care alternatives. Many neuromodulation therapies require extensive medical resources or time to deliver. Thus, the investigators will test two non-invasive technologies administered in a manner that would reduce resources and/or time. Virtual Reality (VR) overlays the sensory system to block the external environment and provide vast range of meaningful sensory experiences. Transcranial Magnetic Stimulation (TMS) involves a magnetic pulse passing through the scalp to depolarize neurons in the outer cortex of the brain, and daily treatments over 6 weeks are currently FDA indicated for the treatment of major depressive disorder. Accelerated TMS is the delivery of treatment in a shorter period of time. The primary objective of this study to demonstrate the preliminary effectiveness, tolerability, and feasibility of these two interventions: Guided Meditation VR for Wellness and Accelerated Transcranial Magnetic Stimulation.

NCT ID: NCT03393312 Recruiting - Dysphoria Clinical Trials

Effects of Transcranial Direct Current Stimulation on Reward Learning in Subclinical Depression.

Start date: February 2, 2018
Phase: N/A
Study type: Interventional

This project will test whether transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex (DLPFC) can alter reward learning behaviour in subclinical depression. tDCS is a neuromodulation technique that uses weak electrical current to increase (anodal stimulation) or decrease (cathodal stimulation) the excitability of the stimulated brain region. A growing body of evidence indicates that repeated administration of prefrontal tDCS can ameliorate symptoms of depression. A main characteristic of depression is that patients show a bias towards processing negative relative to positive information. Previously, we have found that a single session of prefrontal tDCS applied during task performance increased learning rate for reward outcomes in healthy adults. Here, we will test whether stimulation induces a similar behavioural effect in individuals with subclinical depression. We will test the prediction that tDCS will increase learning rates for reward outcomes in a reinforcement learning task. The findings will contribute to understanding the cognitive effects of prefrontal tDCS in subclinical depression. The ultimate aim, to be explored through further studies, is to understand and improve how tDCS might be used in the treatment of depressive disorders.

NCT ID: NCT01101685 Completed - Dysphoria Clinical Trials

Neural Responses and Dysphoria: Modulation by a Pharmacological Probe

Start date: February 2010
Phase: Phase 4
Study type: Interventional

This study aims to improve understanding of how people with low mood and negative feelings (known as dysphoric) may be different from people with normal mood and feelings (nondysphoric) when responding to a variety of social and emotional information. The study will look at the patterns of activity in peoples' brains in situations (presented as a battery of tests) after treatment with a medicine (escitalopram) or a placebo. The results from this study will help to gather information about the effectiveness of the various tests being used in this study in detecting any changes due to treatment with an antidepressant. Half the volunteers taking part in this study will be dysphoric (mildly depressed) whilst the other half of volunteers will be healthy volunteers. It is hoped that the results of this study will provide guidance for assessing effectiveness of new medicines and potentially help with the treatment of depression.